BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 20940416)

  • 21. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
    Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
    Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.
    Blix ES; Irish JM; Husebekk A; Delabie J; Forfang L; Tierens AM; Myklebust JH; Kolstad A
    BMC Cancer; 2012 Oct; 12():478. PubMed ID: 23072591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1.
    Gilling CE; Mittal AK; Chaturvedi NK; Iqbal J; Aoun P; Bierman PJ; Bociek RG; Weisenburger DD; Joshi SS
    Br J Haematol; 2012 Jul; 158(2):216-231. PubMed ID: 22571278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia.
    Liso V; Capalbo S; Lapietra A; Pavone V; Guarini A; Specchia G
    Haematologica; 1999 Mar; 84(3):212-7. PubMed ID: 10189384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation.
    Rodríguez A; Villuendas R; Yáñez L; Gómez ME; Díaz R; Pollán M; Hernández N; de la Cueva P; Marín MC; Swat A; Ruiz E; Cuadrado MA; Conde E; Lombardía L; Cifuentes F; Gonzalez M; García-Marco JA; Piris MA;
    Leukemia; 2007 Sep; 21(9):1984-91. PubMed ID: 17611561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
    Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
    Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
    Choi MY; Kashyap MK; Kumar D
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
    Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.
    Cesano A; Perbellini O; Evensen E; Chu CC; Cioffi F; Ptacek J; Damle RN; Chignola R; Cordeiro J; Yan XJ; Hawtin RE; Nichele I; Ware JR; Cavallini C; Lovato O; Zanotti R; Rai KR; Chiorazzi N; Pizzolo G; Scupoli MT
    Haematologica; 2013 Apr; 98(4):626-34. PubMed ID: 23144194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
    Xu J; Zhou P; Wang W; Sun A; Guo F
    J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates.
    Hartmann EM; Rudelius M; Burger JA; Rosenwald A
    Leuk Lymphoma; 2016; 57(3):563-71. PubMed ID: 26458057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.
    Jia L; Clear A; Liu FT; Matthews J; Uddin N; McCarthy A; Hoxha E; Durance C; Iqbal S; Gribben JG
    Blood; 2014 Mar; 123(11):1709-19. PubMed ID: 24464016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.
    Yeh YY; Ozer HG; Lehman AM; Maddocks K; Yu L; Johnson AJ; Byrd JC
    Blood; 2015 May; 125(21):3297-305. PubMed ID: 25833959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
    Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
    Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
    Wiestner A
    Hematology Am Soc Hematol Educ Program; 2012; 2012():88-96. PubMed ID: 23233565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B cell receptor signaling in chronic lymphocytic leukemia.
    Burger JA; Chiorazzi N
    Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.